Crown Electrokinetics Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Crown Electrokinetics Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $19.70M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $153.0K | Mar 31, 2025 |
| FY2021 | Mar 31, 2020 | $100.0K | Jun 21, 2021 |
| FY2020 | Mar 31, 2019 | $504.8K | Sep 4, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($714.0K) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($781.0K) | Mar 31, 2025 |
| FY2021 | Mar 31, 2020 | ($520.0K) | Jun 21, 2021 |
| FY2020 | Mar 31, 2019 | ($109.2K) | Sep 4, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($25.95M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($28.98M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($14.32M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($16.49M) | Mar 31, 2023 |
| FY2021 | Mar 31, 2021 | ($40.76M) | Jun 21, 2021 |
| FY2021 | Mar 31, 2020 | ($9.60M) | Jun 21, 2021 |
| FY2020 | Mar 31, 2019 | ($4.30M) | Sep 4, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($24.13M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($19.31M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($15.11M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($16.86M) | Mar 31, 2023 |
| FY2021 | Mar 31, 2021 | ($19.35M) | Jun 21, 2021 |
| FY2021 | Mar 31, 2020 | ($7.84M) | Jun 21, 2021 |
| FY2020 | Mar 31, 2019 | ($2.61M) | Sep 4, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.37M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $2.81M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.11M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.50M | Mar 31, 2023 |
| FY2021 | Mar 31, 2021 | $3.54M | Jun 21, 2021 |
| FY2021 | Mar 31, 2020 | $1.83M | Jun 21, 2021 |
| FY2020 | Mar 31, 2019 | $712.1K | Sep 4, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $20.05M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $15.07M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $10.50M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $14.37M | Mar 31, 2023 |
| FY2021 | Mar 31, 2021 | $15.81M | Jun 21, 2021 |
| FY2021 | Mar 31, 2020 | $5.49M | Jun 21, 2021 |
| FY2020 | Mar 31, 2019 | $1.79M | Sep 4, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($18.18M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($16.16M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($11.14M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($8.54M) | Mar 31, 2023 |
| FY2021 | Mar 31, 2021 | ($6.58M) | Jun 21, 2021 |
| FY2021 | Mar 31, 2020 | ($1.04M) | Jun 21, 2021 |
| FY2020 | Mar 31, 2019 | ($1.62M) | Sep 4, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $6.15M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $2.17M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $751.0K | Apr 1, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $34.98M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $9.53M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.59M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $9.65M | Mar 31, 2023 |
| FY2021 | Mar 31, 2021 | $17.52M | Jun 21, 2021 |
| FY2021 | Mar 31, 2020 | $388.6K | Jun 21, 2021 |
| FY2020 | Mar 31, 2019 | $673.0K | Sep 4, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $12.74M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $4.85M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.06M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $664.0K | Mar 31, 2023 |
| FY2021 | Mar 31, 2021 | $934.5K | Jun 21, 2021 |
| FY2021 | Mar 31, 2020 | $7.35M | Jun 21, 2021 |
| FY2020 | Mar 31, 2019 | $4.07M | Sep 4, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $22.24M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $4.68M | Mar 31, 2025 |
| FY2024 | Dec 31, 2022 | $530.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $8.99M | Apr 1, 2024 |
| FY2022 | Mar 31, 2021 | $16.59M | Mar 31, 2023 |
| FY2021 | Mar 31, 2020 | ($6.96M) | Jun 21, 2021 |
| FY2021 | Mar 31, 2019 | ($3.39M) | Jun 21, 2021 |
| FY2020 | Mar 31, 2018 | ($501.8K) | Sep 4, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $652.0K | Apr 1, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($142.94M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($117.00M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($88.01M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($73.69M) | Mar 31, 2023 |
| FY2021 | Mar 31, 2021 | ($57.20M) | Jun 21, 2021 |
| FY2021 | Mar 31, 2020 | ($16.45M) | Jun 21, 2021 |
| FY2020 | Mar 31, 2019 | ($6.84M) | Sep 4, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $13.70M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $1.06M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $821.0K | Apr 1, 2024 |
| FY2021 | Mar 31, 2021 | $15.30M | Jun 21, 2021 |
| FY2021 | Mar 31, 2020 | $48.3K | Jun 21, 2021 |
| FY2020 | Mar 31, 2019 | $99.4K | Sep 4, 2020 |
| FY2020 | Mar 31, 2018 | $168.2K | Sep 4, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $924.0K | Mar 31, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (548) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | (109,044) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (54) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (548) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | (109,044) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (54) | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 790,774 | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | 1,145 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 338,033 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 14.53M | Mar 31, 2023 |
| FY2021 | Mar 31, 2021 | 14.86M | Jun 21, 2021 |
| FY2021 | Mar 31, 2020 | 5.77M | Jun 21, 2021 |
| FY2020 | Mar 31, 2019 | 9.88M | Sep 4, 2020 |